Meredith Cook Sells 400 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 400 shares of the business’s stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $68.96, for a total transaction of $27,584.00. Following the transaction, the vice president now directly owns 80,145 shares of the company’s stock, valued at $5,526,799.20. The trade was a 0.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Meredith Cook also recently made the following trade(s):

• On Thursday, March 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $63.33, for a total transaction of $25,332.00.
• On Thursday, February 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $59.54, for a total value of $23,816.00.

ANI Pharmaceuticals Price Performance

NASDAQ ANIP opened at $69.55 on Wednesday. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $70.00. The stock has a market cap of $1.51 billion, a price-to-earnings ratio of -126.45 and a beta of 0.49. The company’s 50 day moving average is $62.71 and its two-hundred day moving average is $59.22.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ANIP. Guggenheim reiterated a “buy” rating and set a $86.00 price objective on shares of ANI Pharmaceuticals in a research report on Friday, April 11th. StockNews.com lowered shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, April 8th. JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals in a report on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, March 17th. Finally, Jefferies Financial Group began coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 14th. They issued a “buy” rating and a $80.00 price target on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $79.75.

Institutional Trading of ANI Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. US Bancorp DE lifted its stake in shares of ANI Pharmaceuticals by 842.9% during the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock valued at $33,000 after buying an additional 531 shares in the last quarter. KBC Group NV raised its holdings in ANI Pharmaceuticals by 89.2% during the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock valued at $70,000 after acquiring an additional 600 shares during the period. GAMMA Investing LLC lifted its position in shares of ANI Pharmaceuticals by 163.8% in the first quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company’s stock valued at $95,000 after acquiring an additional 881 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of ANI Pharmaceuticals in the fourth quarter worth about $166,000. Finally, Rafferty Asset Management LLC purchased a new stake in shares of ANI Pharmaceuticals during the fourth quarter worth about $200,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.